Reference:	FOI.9280.22
Subject:	Continuous Glucose Monitoring (CGM) NICE Guidance
Date of Request:	30 June 2022

Requested:

NICE have recently updated the guidance on the use of Continuous Glucose Monitoring (CGM) in Type 1 adults, children & young people and Type 2 adults. (NG17, NG18 & NG28)

This new guidance recommends more widespread use of CGM devices.

Please can you tell me:

- What plans the LHB have to implement this updated guidance into a policy and what timescales you are working to?
- What are the steps/ procedures involved in producing the new policy from start to finish?
- If you are not willing to implement the NICE recommendations can you provide reasons why this would be?

Response:

Hywel Dda University Health Board (UHB) confirms that the updated National Institute for Health and Care Excellence (NICE) guidance on the use of Continuous Glucose Monitoring (CGM) is already in place within the Paediatrics Departments for Children and Young People (CYP). CGM is used at diagnosis or as soon as possible afterwards, where the team offer Dexcom G6 or Libra 2.

Within the adult service, the UHB follows the Health Technology Wales (HTW) guidance for glucose monitoring for adults, which was issued in September 2021. Details of the guidance can be accessed via the attached weblink:
https://healthtechnology.wales/reports-guidance/freestyle-libre-flash-glucose-monitoring/

Additionally, the UHB will be comparing the new NICE recommendations to the guidance currently in use to identify any changes that need to be made to the eligibility criteria. The NICE guidance is also currently being utilised to assist the UHB with the updating of the wording for Type 2 diabetes policy and procedures.

The UHB confirms that if any changes to the formulary and/or its Guidelines for Home Glucose Monitoring (Primary, Community, Acute and Mental Health Care) and Medicines Management Standard Operating Procedures are required, the UHB would prepare a draft document which would be sent to various stakeholders within the UHB for consultation. Any comments received on the document would be addressed prior to the document being presented for approval at the UHB's Medicines Management Operational Group (MMOG), which meets bi-monthly.